drugset / Trial / NCT07066995
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
Autologous T-cells engineered to express CARs targeting Mesothelin and Claudin18.2, for Unresectable locally advanced or metastatic pancreatic adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC), administered as two separate sequential infusions following lymphodepleting chemotherapy
Timeline
- Start
- 2025-04-29
- Primary completion
- 2027-12-10
- Completion
- 2028-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Claudin18.2 CAR-T cells | Cell therapy | — | Intravenous |
| Subject | Mesothelin and Claudin 18.2 CAR-T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |